Filing Details

Accession Number:
0001415889-24-023787
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-09-20 17:35:27
Reporting Period:
2024-09-18
Accepted Time:
2024-09-20 17:35:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1923840 Third Harmonic Bio Inc. THRD Pharmaceutical Preparations (2834) 834553503
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1946505 Julie Person C/O Third Harmonic Bio, Inc.
1700 Montgomery Street, Suite 210
San Francisco CA 94111
Chief Administrative Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-09-18 503 $4.20 503 No 4 M Direct
Common Stock Disposition 2024-09-18 503 $14.00 0 No 4 S Direct
Common Stock Disposition 2024-09-19 9,497 $4.20 9,497 No 4 M Direct
Common Stock Disposition 2024-09-19 9,497 $14.29 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Option Grant (right to buy) Disposition 2024-09-18 503 $0.00 503 $4.20
Common Stock Employee Option Grant (right to buy) Disposition 2024-09-19 9,497 $0.00 9,497 $4.20
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
165,459 2032-07-27 No 4 M Direct
155,962 2032-07-27 No 4 M Direct
Footnotes
  1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated March 27, 2024.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.53 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. 25% of the total shares vest on June 20, 2023, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.